Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00796887 · ClinicalTrials.gov registry record · Phase 2
Randomized, Controlled Trial of Extended-Release Niacin (Niaspan®) to Augment Subacute Ischemic Stroke Recovery
A Phase 2 study, sponsored by Henry Ford Health System.
- Completed
- Registry status
- Phase 2
- Development phase
- 28
- Enrollment target
NCT00796887 is a Phase 2 study that has completed, run by Henry Ford Health System. The registered enrollment target is 28 participants.
The verdict
NCT00796887, a Phase 2 study, has completed, sponsored by Henry Ford Health System.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 28 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the safety, tolerability, and to explore the possible benefit of extended-release niacin (Niaspan®) in attempting to improve the recovery of patients after ischemic stroke.
Interventions
- DRUG Placebo
- DRUG Extended-Release Niacin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2009-04 |
| Est. Completion | 2012-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00796887
The ClinicalTrials.gov registry entry for NCT00796887 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 28 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Henry Ford Health System, which has 234 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00796887 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00796887 about?
NCT00796887 is a clinical study titled "Randomized, Controlled Trial of Extended-Release Niacin (Niaspan®) to Augment Subacute Ischemic Stroke Recovery". The purpose of this study is to determine the safety, tolerability, and to explore the possible benefit of extended-release niacin (Niaspan®) in attempting to improve the recovery of patients after ischemic stroke.
What is the current status of trial NCT00796887?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 28 participants. The study started on 2009-04. Estimated completion is 2012-08.
What interventions are being tested in trial NCT00796887?
The interventions under investigation include: Placebo (DRUG), Extended-Release Niacin (DRUG).
Who is sponsoring clinical trial NCT00796887?
This trial is sponsored by Henry Ford Health System, which has 234 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.